Pharmaceutical Technology-07-02-2008
Pharmaceutical Technology
Coming Down the Pike: Protein-Substrate Binding
July 02, 2008
News
32
7
Drugmakers seeking to block the activity of a protein may have a new strategy at their disposal.
Trends: Industry Job Cuts
July 02, 2008
News
32
7
Staff reductions are not surprising with the state of the economy and falling pharmaceutical sales.
Self-Emulsifying Drug Delivery Systems
July 02, 2008
Online Exclusive
32
7
This review article explains how self-emulsifying drug delivery systems can increase the solubility and bioavailability of poorly soluble drug.
A Path to Quality and Compliance
July 02, 2008
Online Exclusive
32
7
A new book explains process analytical technology, drug stability, and quality.
Improved Mass Determination of Poly(ethylene glycols) by Electrospray Ion-Mobility Time-of-Flight Mass Spectrometry Coupled with Ion–Molecule Reactions
July 02, 2008
Special Section: Polymers
32
7
The authors developed a method to accurately measure the average molecular weight of large poly(ethylene glycols) (PEGs) using ion-mobility time-of-flight mass spectrometry coupled with gas-phase ion–molecule reactions.
Excipients in Polymeric Drug Delivery and Formulations
July 02, 2008
Special Section: Polymers
32
7
A roundtable with John Doney, Jiao Yang, Hans Baer, and Elena Draganoiu.
ePedigree: Using the Gift of Time Wisely
July 02, 2008
Viewpoint
32
7
The year 2011 may seem far off, but there is much to do to prepare for electronic pedigrees.
Variables Affecting Reconstitution Time of Dry Powder for Injection
July 02, 2008
Peer-Reviewed Research
32
7
The authors describe the factors affecting reconstitution time of dry powder for injection and classifies them as intrinsic and extrinsic parameters.
Report From: The Netherlands
July 02, 2008
News
32
7
A growing preference for public-private partnerships is spurring innovation and technology among Dutch pharmaceutical companies.
Manufacturing Insights: Pfizer
July 02, 2008
Special Report
32
7
Natale S. Ricciardi, president of Pfizer Global Manufacturing and senior vice-president of Pfizer, discusses the company's new manufacturing focus that features plant network optimization, increased outsourcing, and greater adoption of agile or lean manufacturing.
Inside IPEC: Dual-Use Labeling
July 02, 2008
Inside IPEC
32
7
Clear labels for substances that can be used as excipients, APIs, or both are critical to end-product use.
Deviations and Delays
July 02, 2008
Agent-In-Place
32
7
They may have seemed harmless at first, but these ideas took a big bite.
Talked to Your Peers Lately?
July 02, 2008
PharmTech Talk
32
7
Forums, blogs, and more can spark innovation.
The Benefits and Challenges of PEGylating Small Molecules
July 02, 2008
Special Section: Polymers
32
7
Polyethylene glycol (PEG) conjugation is a highly effective technical and commercial strategy to develop macromolecules. The authors explain the benefits and process of PEGylation and how it may be applied to small molecules.
How to Pay for it All?
July 02, 2008
From The Editor
32
7
With no economic relief in sight, industry, like all of us, is grappling with high-and new-costs.
Celebrating 25 Years of Orphan Drugs
July 02, 2008
Washington Report
32
7
New scientific discoveries promise to expand treatments for rare and neglected diseases.
Help Your Contract Laboratory Help You
July 02, 2008
Outsourcing Outlook
32
7
Providing the right information upfront may ease new requirements to assess solvent levels.
Compliance Risk Management Using a Top-Down Validation Approach
July 02, 2008
Peer-Reviewed Research
32
7
Patient safety must be the primary concern of any validation effort. The author explains how a risk-based approach to validation and compliance follows naturally from this premise.
A Reality Check on Emerging Markets
July 02, 2008
Special Report
32
7
Recent reports discuss the future of pharma's emerging markets.
In the Spotlight July 2008
July 02, 2008
In the Spotlight
32
7
Editors' Picks of Pharmaceutical Science & Technology Innovations
Charting API Market Growth and Opportunity
July 02, 2008
Ingredients Insider
32
7
The year 2007 was slow for approvals for new molecular entities and overall pharmaceutical industry growth. Big Pharma seeks relief in a growing biologics portfolio.
Tipping the Scales in Manufacturing Investment
July 02, 2008
Special Report
32
7
The pharmaceutical majors invest in biologics production capacity as they advance restructuring programs and build their pipelines